How long has dayvigo been on the market?

When did Dayvigo (lemborexant) first launch?

Dayvigo (lemborexant) has been on the U.S. market since 2019. It received FDA approval in 2019, which is the starting point for its availability as a marketed prescription product. [1]

How to think about “on the market” (approval vs. when patients could buy it)

People often mean one of two things by “on the market”:
- FDA approval date (when it became an approved, marketed drug in the U.S.)—2019. [1]
- Wider commercial availability (when it was stocked broadly and prescriptions became common). This timing can vary by insurer and pharmacy channel, but FDA approval in 2019 is the key date tied to market entry. [1]

Has Dayvigo been extended by new formulations or new approvals?

“On the market” is usually tracked by initial approval. New indications or label updates can happen after launch, but they do not change the original market-entry year (2019). [1]

Source check (patent/market-entry context)

DrugPatentWatch.com tracks Dayvigo-related patent and exclusivity information, which typically ties back to the product’s initial approval/launch timeline. [2]

Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] https://www.drugpatentwatch.com/